PHASE-I EVALUATION AND PHARMACOKINETICS OF TIAZOFURIN (2-BETA-D-RIBOFURANOSYLTHIAZOLE-4-CARBOXAMIDE, NSC-286193)
- 1 January 1985
- journal article
- research article
- Vol. 45 (6) , 2859-2865
Abstract
Tiazofurin (2-.beta.-D-ribofuranosylthiazole-4-carboxamide, TCAR, Riboxamide, NSC 286193) is a novel C-nucleoside with antitumor activity against several murine tumor models, including Lewis lung carcinoma. The mechanism whereby this compound exerts its antineoplastic effects is most likely related to a state of guanine nucleotide depletion whereby the anabolite, thiazole-4-carboxamide adenine dinucleotide, potently inhibits IMP dehydrogenase. This Phase I study was designed to determine the maximally tolerated dose of tiazofurin administered on a 5-day, every-28-day schedule. Tiazofurin levels were measured using a high-pressure liqiud chromatography assay and pharmacokinetic studies were performed in patients treated at each dose level. Nineteen patients received a total of 24 courses of the drug in doses ranging from 550-2200 mg/m2. The dose-limiting toxicities were pleuropericarditis and a general illness best described as a viral-like syndrome (manifested by severe malaise, headaches, myalgias, fever, nausea, vomiting and diarrhea). Other toxicity included myelosuppression, hyperuricemia, elevated serum creatine phosphokinase and serum glutamic oxaloacetic transaminase, conjunctivitis, mucositis and desquamation of the palms of the hands. Plasma clearance of tiazofurin followed a biexponential pattern with a harmonic mean terminal half-life of 7.6 h. The mean volume of distribution at steady state was 30 l/m2 and the mean plasma clearance was 3 l/h per m2. The total cumulative urinary excretion ranged from 15-49%. The maximally tolerated dose of tiazofurin on a 5-day schedule was 1650 mg/m2. The recommended dose for Phase II evaluations is 1100 mg/m2 for 5 days. Exploration of other schedules which might allow administration of more tiazofurin combined with biochemical studies including thiazole-4-carboxamide adenine dinucleotide measurements would be desirable.This publication has 9 references indexed in Scilit:
- EFFECTS ON HUMAN PERIPHERAL LYMPHOCYTES OF INVIVO ADMINISTRATION OF 9-BETA-D-ARABINOFURANOSYL-2-FLUOROADENINE-5'-MONOPHOSPHATE (NSC-312887), A NEW PURINE ANTIMETABOLITE1984
- THE DISPOSITION AND METABOLISM OF TIAZOFURIN IN RODENTS, RABBITS, AND DOGS1984
- Interactions of lectins and monoclonal antibodies with human mononuclear cells. I. Specific inhibition of OKT4 and OKT8 binding by Ricinus communis agglutinin and wheat germ agglutinin.The Journal of Immunology, 1983
- ACTION OF 2-BETA-D-RIBOFURANOSYLTHIAZOLE-4-CARBOXAMIDE (TIAZOFURIN) IN CHINESE-HAMSTER OVARY AND VARIANT CELL-LINES1983
- ACTIVITY AND METABOLISM OF 2-BETA-D-RIBOFURANOSYLTHIAZOLE-4-CARBOXAMIDE IN HUMAN LYMPHOID TUMOR-CELLS IN CULTURE1983
- Analysis of riboxamide in plasma by high-performance liquid chromatography using automated column switchingJournal of Chromatography B: Biomedical Sciences and Applications, 1983
- Studies on the mechanism of action of 2-β-d-ribofuranosylthiazole-4-carboxamide (NSC 286193)-IIBiochemical Pharmacology, 1982
- Initial studies on the mechanism of action of a new oncolytic thiazole nucleoside, 2-β-d-ribofuranosylthiazole-4-carboxamide NSC 286193)Biochemical Pharmacology, 1982
- THE BIOCHEMICAL AND CLINICAL CONSEQUENCES OF 2'-DEOXYCOFORMYCIN IN REFRACTORY LYMPHOPROLIFERATIVE MALIGNANCY1981